{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/26/3318449/0/en/Monopar-Presents-New-Analyses-of-Phase-3-FoCus-Data-at-EAN-2026-Showing-Greater-Neurologic-and-Global-Clinical-Benefit-with-ALXN1840-Versus-Standard-of-Care-in-Wilson-Disease.html", "message": "News view counter 819177 successfully enlarged"}